SeekingAlpha · Aug 10, 2026
Nippon Shinyaku Co., Ltd. 2027 Q1 - Results - Earnings Call Presentation
2026-08-10. The following slide deck was published by Nippon Shinyaku Co., Ltd.
NP
OTC · NPPNY
Nippon Shinyaku Co., Ltd.
Healthcare · Drug Manufacturers - Specialty & Generic
$5.61
Down-$0.50 (-8.18%)
Updated Aug 18, 2026, 12:37 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.47B
- P/E ratio
- 11.76
- Dividend yield
- 3.69%
- 52-week range
- — – —
- Volume
- 125
- Avg. volume
- 4.3K
Price performance
NPPNY price history
1M range · 0 trading sessions · Daily adjusted prices
NPPNY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest NPPNY news
The latest Smart Investors Daily articles mentioning NPPNY.
Stock researchCompany · Overview
NPPNY research
Overview
Company profile and research snapshot.
Company profile
NIPPON SHINYAKU UNSP/ADR
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
SeekingAlpha · May 15, 2026
Nippon Shinyaku Co., Ltd. 2026 Q4 - Results - Earnings Call Presentation
2026-05-15. The following slide deck was published by Nippon Shinyaku Co., Ltd.
GlobeNewswire Inc. · Jan 27, 2025
AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease
AB2 Bio has signed an option and licensing agreement with Nippon Shinyaku for the commercialization of Tadekinig alfa to treat a rare autoimmune disease in the U.S. AB2 Bio will receive up to $36 million in early payments and up to $650 million in potential milestone and royalty payments.
GlobeNewswire Inc. · Nov 13, 2024
Nippon Shinyaku and Atsena Therapeutics enter into an Exclusive Strategic Collaboration for ATSN-101 in the U.S. and Japan
Nippon Shinyaku and Atsena Therapeutics have entered into an exclusive license agreement for the commercialization of ATSN-101, Atsena's investigational gene therapy for Leber congenital amaurosis caused by GUCY2D mutations, in the U.S. and Japan.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
